Clinical Trials Logo
  1. Home
  2. Substance Dependence
  3. NCT00605241

A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward

Substance Dependence Clinical Trial

Official title:
A Randomized, Double-bind, Placebo Controlled, Two-way Cross-over Study to Assess the Effects of a Single Dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward

Clinical Trial Summary

GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders. This study will asses the effects of a single dose of GSK598809 in modulating nicotine reward in 2 cohorts of otherwise healthy male volunteers who smoke. Each cohort of subjects will receive a single dose of placebo or GSK598809 in two dosing sessions binded crossover fashine. There will be a washout period of at least seven days between each session.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00605241
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date February 25, 2008
Completion date March 20, 2009
View Details
See also
  Status Clinical Trial Phase
Completed NCT00887367 - EtOH Interaction Study Phase 1
Completed NCT01036061 - GSK618334 Repeat Dose Study Phase 1
Completed NCT01189799 - Motivational Therapy for Substance Users With Depression N/A
Completed NCT01381133 - Adolescent Outpatient and Continuing Care Study Phase 3
Recruiting NCT04430257 - Pre-exposure Prophylaxis (PrEP) for Health N/A
Completed NCT01128140 - Efficacy Trial of Warrior Check-Up Phase 2
Completed NCT03767907 - Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial N/A
Recruiting NCT05833399 - Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
Withdrawn NCT01515917 - Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI) N/A
Completed NCT00208143 - Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Phase 4
Withdrawn NCT03762798 - Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone N/A
Completed NCT03048552 - Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3 N/A
Active, not recruiting NCT04768920 - Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD) N/A
Recruiting NCT05410561 - Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients N/A
Recruiting NCT05679284 - A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
Withdrawn NCT00908206 - Effects of GSK598809 on Brain Activation in Abstinent Alcoholics Phase 1
Recruiting NCT05348317 - Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders N/A
Recruiting NCT01741415 - Distress Tolerance Treatment for Substance Users Phase 2
Active, not recruiting NCT01621711 - Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care N/A
Active, not recruiting NCT00609089 - Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Phase 1/Phase 2